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Abstract
To assess the impact of HIV-infection and highly active anti-retroviral treatment in mitochondria and apoptotic activation of caspases dur-
ing pregnancy and their association with adverse perinatal outcome. Changes of mitochondrial parameters and apoptotic caspase activation
in maternal peripheral blood mononuclear cells were compared at first trimester of pregnancy and delivery in 27 HIV-infected and -treated
pregnant women versus 24 uninfected pregnant controls. We correlated immunovirological, therapeutic and perinatal outcome with experi-
mental findings: mitochondrial DNA (mtDNA) content, mitochondrial protein synthesis, mitochondrial function and apoptotic caspase activa-
tion. The HIV pregnancies showed increased adverse perinatal outcome (OR: 4.81 [1.14–20.16]; P < 0.05) and decreased mtDNA content
(42.66  5.94%, P < 0.01) compared to controls, even higher in na€ıve participants. This depletion caused a correlated decrease in mito-
chondrial protein synthesis (12.82  5.73%, P < 0.01) and function (20.50  10.14%, P < 0.001), not observed in controls. Along preg-
nancy, apoptotic caspase-3 activation increased 63.64  45.45% in controls (P < 0.001) and 100.00  47.37% in HIV-pregnancies
(P < 0.001), in correlation with longer exposure to nucleoside analogues. HIV-infected women showed increased obstetric problems and
declined genetic and functional mitochondrial parameters during pregnancy, especially those firstly exposed to anti-retrovirals. The apop-
totic activation of caspases along pregnancy is emphasized in HIV pregnancies promoted by nucleoside analogues. However, we could not
demonstrate direct mitochondrial or apoptotic implication in adverse obstetric outcome probably because of the reduced sample size.
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Introduction
The effectiveness of highly active antiretroviral treatment (HAART)
regimens in reducing mother-to-child vertical transmission (MTCT) of
HIV-infection and in delaying disease progression has been demon-
strated and should therefore be offered to all pregnancies [1–3].
Anti-retroviral (ARV) treatment comprised of two nucleoside reverse
transcriptase inhibitors (NRTIs) and non-nucleoside reverse
transcriptase inhibitor (NNRTI) or protease inhibitor (PI) is recom-
mended in pregnancy by the United States, World Health Organization
and European guidelines [4, 5]. Additional measures including selec-
tive caesarean or avoidance of breastfeeding are strongly recom-
mended. However, adverse pregnancy outcome have been
increasingly reported by several observational studies in HIV-infected
women exposed to HAART [6–11]. Anti-retrovirals and HIV-infection
have been associated with pre-eclampsia, stillbirth, pre-term labour,
low birth weight and intrauterine growth restriction (IUGR) [12–17].
One of the most serious complications associated with ARVs is
mitochondrial toxicity. Mitochondrial-derived clinical effects of NRTI
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have been firmly established in HIV-infected non-pregnant adults
[18–20]. These negative effects depend on the capacity of NRTIs
to inhibit DNA polymerase gamma, the enzyme devoted to mito-
chondrial DNA (mtDNA) replication, leading to a decrease in
mtDNA copy number and quality, which may, finally, cause mito-
chondrial dysfunction [18]. Depletion of mtDNA has been exten-
sively described in different tissues of human and animal models
(placenta, foetal cord blood, heart, adipose tissue, skeletal muscle,
brain and kidney, among others) leading to mitochondrial morpho-
logic, metabolic and energetic abnormalities [21–25]. Such mito-
chondrial disturbances are enhanced by HIV, which has been
additionally blamed for triggering apoptosis [26]. Associated clinical
syndromes have been expanded to include lipoatrophy, peripheral
neuropathy, cardiomyopathy, lactic acidosis and hepatic steatosis
[27, 28]. Moreover, accelerated ‘mitochondrial aging’ associated
with ARV may contribute to cardiovascular disease, malignancies
and frailty [29].
Maternal death has been described as a result of lactic acidosis in
women receiving long-term treatment with a combination of NRTI
[30, 31], especially in the third trimester of pregnancy and in ARV
schedules including two NRTIs. Fortunately, severe maternal mito-
chondrial toxicity associated with NRTI during pregnancy appears to
be rare and is reversible on treatment discontinuation. However,
milder forms of mitochondrial toxicity are commonly reported and
may have future long-term effects.
Although ARV use during pregnancy is considered safe, data on
ARV and pregnancy, especially in HAART, are insufficient, and safety
and long-term health consequences are currently unknown. The few
studies on long-term HAART exposure have focused on foetal and
perinatal ARV effects [32–37], but rarely on maternal-related prob-
lems which may, in turn, affect children.
We recently described that HAART toxicity may cause subclini-
cal mitochondrial damage in pregnant women and their new-
born [38] by reducing mtDNA levels, mitochondrial protein
synthesis and mitochondrial function. Additionally, increased apop-
tosis through caspase-3 activation was observed in HIV-
pregnant women, but not in their children, cross-sectionally, at
delivery.
The aim of this study was to investigate the impact of HIV-infec-
tion and HAART on mitochondria and apoptotic caspase activation
during pregnancy to assess their implication in the increase of
adverse perinatal outcome characteristic of HIV-pregnancies to estab-
lish potential prenatal prognosis markers.
Materials and methods
Design
We performed a single-site, controlled observational study without inter-
vention to determine longitudinal mitochondrial toxicity and apoptotic
caspase activation (from the first trimester of gestation to delivery) in
maternal peripheral blood mononuclear cells (PBMC) of HIV-infected
pregnancies compared to uninfected controls.
Study population
Twenty-seven asymptomatic HIV-1-infected and twenty-four uninfected
women were consecutively included during routine prenatal care at first
trimester of gestation in the Hospital Clinic of Barcelona (Barcelona,
Spain).
Controls and cases were age and parity matched. The inclusion crite-
ria for pregnant women were: >18 years of age, single pregnancy, deliv-
ery >22 weeks of gestation and, for HIV-patients, previous diagnosis of
HIV-infection.
Patients taking potentially toxic drugs for mitochondria and with
familial history of mitochondrial disease were excluded.
The Ethical Committee of our hospital approved the study and it was
performed following the Declaration of Helsinki. All participants provided
written consent.
Clinical results
A database was created to collect epidemiological, immunovirological,
therapeutic, obstetric, perinatal and experimental data.
Maternal epidemiological parameters included information on mater-
nal age, race and illegal substance abuse.
Immunovirological parameters for HIV-infected women consisted in
quantifying comorbidity with HCV infection, plasmatic HIV-viral load (by
rtPCR), CD4+ T-cell count (by flow cytometry) and time from HIV infec-
tion to delivery.
Therapy was administered to all HIV-pregnant women following inter-
national guidelines. HIV-infected women were stratified according to
ARV use during pregnancy. Women na€ıve for ARV before pregnancy
started HAART (double-NRTI schedule and either one PI or NNRTI drug)
during the second trimester of gestation to prevent MTCT.
Information regarding obstetric and perinatal outcome included: par-
ity, mode of delivery, gestational diabetes mellitus, pre-eclampsia (new
onset of hypertension of >140 mmHg systolic or >90 mmHg diastolic
pressure and >300 mg proteins/24 hrs urine after 20 weeks of gesta-
tion), foetal death (>22 weeks of pregnancy), gestational age at delivery,
pre-term birth (<37 weeks of gestation), birth weight, small newborn for
gestational age (<10th percentile), 5-min Apgar score <7, neonatal
admission to intensive care unit and global adverse perinatal outcome.
Finally, experimental data included maternal measures of mitochon-
drial and apoptotic caspase activation at first trimester of gestation and
delivery.
Sample collection and processing
At the first trimester of pregnancy and immediately after delivery, 20 ml
of peripheral blood was collected in EDTA tubes to isolate PBMC by
Ficoll gradient and stored at 80°C until analysis. Protein content was
measured by Bradford protein dye binding-based method [39].
Mitochondrial studies in maternal PBMC
Mitochondrial DNA quantification
Total DNA was extracted by phenol-chloroform procedure. A fragment
of mitochondrial DNA-encoded ND2 and nuclear DNA-encoded 18SrRNA
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genes were amplified separately in triplicate by quantitative rtPCR using
the Roche Lightcycler-thermocycler [20]. Mitochondrial DNA content
was expressed as the ratio between mitochondrial and nuclear DNA
amount (ND2mtDNA/18SrRNA nDNA content).
Mitochondrial protein synthesis
We performed Western blotting of 20 lg total cell protein through 7/
13% SDS-PAGE and posterior immunoquantification of the mitochon-
drial DNA-encoded and located COXII subunit (25.6 kD) with respect to
the nuclear DNA-encoded and mitochondrially located COXIV subunit
(15 kD) to compare relative mitochondrial to nuclear protein synthesis
(COXII/COXIV) [20].
Mitochondrial enzymatic function
Mitochondrial respiratory chain complex II+III (CII+III) enzymatic activi-
ties were measured by spectrophotometry according to Rustin et al.
[37, 40] by following the increase in absorbance at 550 nm of reduced
cytochrome c generation (complex III product) after succinate addition
(complex II substrate). Specific enzymatic activities were expressed as
nanomols of product per minute and milligram of protein (nmols/
min.mg prot).
Apoptotic caspase activation studies
We performed Western blotting of 20 lg total cell protein by 7/13%
SDS-PAGE and posterior immunoanalysis of active (cleaved) caspase-3
pro-apoptotic protein expression (17–19 kD) normalized by the content
of b-actin (47 kD) as a cell loading control. Results were expressed as
caspase-3/b-actin relative content and were interpreted as a marker of
advanced apoptotic events [41].
Additionally, caspase-9 enzymatic activity was measured by means of
the luminescent assay Caspase-Glo Assay (Ref: G8210, Promega Cor-
poration, Madison, WI 53711 USA) using 20 lg of PBMCs’ protein.
Briefly, 50 ll of diluted sample and 50 ll of kit Caspase-Glo reagent
were mixed in an opaque reading multiwell plate following manufacturer’s
instructions. After 36 min. of incubation, the plate was read in a ModulusTM
II Microplate Multimode Reader and caspase- 9 activity was calculated
based on relative luminescent units normalized to sample protein amount.
Statistical analysis
Clinical and epidemiological parameters were expressed as means and
range interval and experimental results as means and S.E.M. or as a
percentage of increase/decrease at delivery compared to first trimester
of pregnancy.
Adverse perinatal outcome, mitochondrial and apoptotic caspase activa-
tion results of HIV-infected women were compared to those of uninfected
controls to assess the impact of HIV and/or ARV. Additionally, different cor-
relations were sought between: molecular and functional mitochondrial
parameters (to ascertain dependence of mitochondrial function on mito-
chondrial genome) and clinical and experimental data (to assess mitochon-
drial or apoptotic basis of obstetric and perinatal outcome).
Nonparametric tests were used to determine: case–control differ-
ences (Mann–Whitney independent sample analysis), odds ratio
(chi-squared test) and parameter correlation (Spearman’s rank coeffi-
cient). Significance was set at 0.05.
Results
Clinical data
Table 1 shows epidemiological characteristics of the participants and
immunovirological and therapeutic data of HIV mothers. All pregnant
women were Caucasian, ranging 25–42 years. Non-significant differ-
ences were observed in maternal clinical data between HIV-positive
and HIV-negative women.
Most HIV-infected women were under HAART before pregnancy
(85%) and only four cases (15%) were ARV-na€ıve and started HAART
at the second trimester of gestation. Highly active ARV treatment was
given to all patients at delivery to avoid MTCT, consisting of two NRTI
and either PI (55.5%) or NNRTI (29.5%). The mean time of HIV-infec-
tion and HAART treatment prior to delivery were 84 and 48 months
respectively. At delivery, all women had undetectable viral load and
received at least 6 months of double-NRTI treatment. Neither patients
nor controls presented clinical manifestations of mitochondrial toxicity.
Perinatal outcome
Table 2 shows obstetric and neonatal outcome of the study cohort.
All infants were HIV-uninfected with no clinical symptoms of mito-
chondrial toxicity, and all received 6-week zidovudine chemoprophy-
laxis to prevent MTCT. These pregnancies showed a trend to
increased gestational diabetes (7.4% versus 4.0%), decreased gesta-
tional age at delivery (37.5 versus 38.6), pre-term birth (25.9% ver-
sus 8.0%), reduced birth weight (2879 g versus 3170 g), small
newborn for gestational age (22.2% versus 4.0%) and intensive care
unit admission (11.1% versus 4.0%). However, only global adverse
perinatal outcome (pre-term birth and small for gestational age
events) were significantly increased among HIV-positive pregnancies
[40.7% versus 12.0%, OR: 4.81 (1.14–20.6); P < 0.05].
Mitochondrial and apoptotic maternal PBMC
analysis
Table S1 shows raw data and statistics of all tested experimental
parameters.
MtDNA content
A highly significant progressive reduction of PBMC mtDNA content
was observed in HIV pregnancies (42.66  5.94%, P < 0.01), not
observed in uninfected pregnant controls (18.34  11.73%,
P = NS), being even greater in na€ıve HIV-infected pregnant women
(50%, P = NS; data not shown).
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Mitochondrial protein synthesis and function
Along pregnancy, HIV women also showed a significant decrease in
the mitochondrial protein synthesis rate and function, not observed in
controls (Fig. 1).
The protein synthesis (COXII/IV expression ratio; Fig. S1)
dropped 12.82  5.73% in HIV mothers (P < 0.01) but only
6.25  11.25% in controls (P = NS), and mitochondrial respiratory
chain activity of complex II+III significantly decreased in HIV-infected
mothers (20.50  10.14%, P < 0.001), but not significantly in con-
trols (6.64  10.39%, P = NS).
Apoptotic caspase activation
Along pregnancy, HIV-infected pregnant women and healthy controls
presented a marked and significant increase in apoptotic caspase-3
activation of 100.00  47.37% and 63.64  45.45%, respectively,
with respect to baseline (P < 0.001 in both cases) (Fig. 1 and
Fig. S1). This difference in the apoptotic caspase-3 activation
between cases and controls was significant (P < 0.05). Similar find-
ings were observed in the measurement of Caspase-9 enzymatic
activity by means of apoptotic increase along pregnancy in both
cohorts of HIV-infected women and uninfected controls
(88.38  41.88 versus 15.76  36.83, respectively, P = NS), higher
for HIV patients (data not shown).
Associations between molecular and clinical
parameters
Genetic and functional mitochondrial parameters
In treated HIV-infected pregnant women, the mitochondrial genome
content was positively and significantly correlated with mitochondrial
function measured as CII+CIII enzymatic activity in the first trimester
of gestation (P < 0.05, R2 = 0.16; Fig. 2A).
The mitochondrial genome level was also positively and signifi-
cantly correlated with mitochondrial protein synthesis, by COXII/IV
measurement, in HIV-positive pregnancies at delivery (P < 0.05;
R2 = 0.19; Fig. 2B).
Mitochondrial and apoptotic parameters and
immunovirological and therapeutic features
A significant, positive correlation was found between increased cas-
pase-3 activation and longer exposure to NRTI prior to pregnancy, in
the first trimester of gestation (P < 0.05; R2 = 0.16; Fig. 3A) and at
delivery (data not shown).
Table 1 Epidemiologic, immunovirologic and therapeutic characteristics of HIV-infected and uninfected pregnant women
HIV-positive (n = 27) HIV-negative (n = 24) P
Maternal age at delivery* 34.7 (27–42) 33.6 (25–41) NS
Illegal drug use, N (%) 0 0 –
Alcohol use, N (%) 0 0 –
HCV infection, N (%) 3 (11.1) 1 (4) NS
HIV RNA copies per ml at delivery* 62.3 (49–250) – –
CD4 T-cell count per ml at delivery* 560.2 (97–1242) – –
Time from diagnosis of HIV infection to delivery (months)* 84 (4–228) – –
NRTI before pregnancy (months)* 48 (0–106) – –
NNRTI before pregnancy (months)* 3 (0–86) – –
PI before pregnancy (months)* 12 (0–97) – –
NA€IVE (HAART 2nd–3rdtrimesters), N (%) 4 (15) – –
HAART all trimesters, N (%) 23 (85) – –
2 NRTI+1 PI, N (%) 15 (55.5)
2 NRTI+1 NNRTI, N (%) 8 (29.5)
*Data are presented as means and range interval.
HCV: hepatitis C virus; HIV: human immunodeficiency virus; HAART: highly active antiretroviral treatment; NRTI: nucleoside-analogue reverse
transcriptase inhibitor; NNRTI: non-nucleoside analogue reverse transcriptase inhibitor; NS: not significant; PI: protease inhibitors; RNA: ribonu-
cleic acid; N: number.
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A significant, positive correlation was also found between
increased caspase-3 activation in the first trimester and longer HIV
infection (P < 0.05; R2 = 0.20; Fig. 3B).
No correlations were found between mitochondrial maternal
experimental parameters and immunovirological status.
Mitochondrial and apoptotic parameters and obstetrics results
The global adverse perinatal outcome were significantly increased in
HIV pregnancies, but did not correlate with mitochondrial or apoptotic
findings.
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Fig. 1Mitochondrial parameters and apoptotic caspase-3 activation. Percentage of increase/decrease from first trimester to delivery of mitochondrial
parameters or apoptotic caspase-3 activation in HIV participants and uninfected controls along pregnancy. MtDNA: mitochondrial DNA; COX-II/IV:
Mitochondrial protein synthesis; CII+III: mitochondrial complex II+ complex III enzymatic activity; caspase-3/b-Actin: apoptotic caspase-3 activation.
*P < 0.01/**P < 0.001.
Table 2 Obstetric and neonatal outcome of the study cohorts
HIV positive (n = 27) HIV negative (n = 24) OR (95% CI)
Gestational diabetes mellitus, N (%) 2 (7.4) 1 (4) 1.84 (0.15–21.7)
Pre-eclampsia, N (%) 0 0 –
Foetal death, N (%) 0 0 –
Gestational age at delivery (weeks)* 37.5 (32.2–41.2) 38.6 (38.3–40.3) P = NS
Preterm birth (<37 weeks of gestation), N (%) 7 (25.9) 2 (8) 3.85 (0.71–20.7)
Birth weight (g)* 2879 (1940–4040) 3170 (3130–3320) P = NS
Small newborn for gestational age (<10th percentile), N (%) 6 (22.2) 1 (4) 6.51 (0.72–59.19)
5-min Apgar score <7, N (%) 0 0 –
Neonatal intensive care unit admission, N (%) 3 (11.1) 1 (4) 2.87 (0.28–29.67)
Global adverse perinatal outcome, N (%) 11 (40.7) 3 (12) 4.81 (1.14–20.16)
P < 0.05
*Data are presented as means and range interval.
95% CI: 95% confidence interval of the mean; N: number; NS: not significant; OR: odds ratio.
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Discussion
Anti-retrovirals are indispensable in the treatment and prevention of
HIV infection. Although their use during pregnancy is considered safe,
there are still lingering concerns about long-term health conse-
quences.
Several studies have demonstrated mitochondrial toxicity in ani-
mal models, HIV-infected infants and adults on NRTI therapy and
newborns exposed in utero to ARVs [22, 24, 37, 38, 47], but it is cur-
rently unknown whether HIV-pregnancy may be an additional risk for
the onset of mitochondrial toxicity.
Several physiopathological mechanisms have been proposed to
explain the adverse clinical effects in HIV pregnancies. Mitochondrial
bioenergetics conditions foetal growth and early postnatal adaptation.
Given that mitochondria are exclusively inherited from the maternal
ovum, early exposure of the ova and the mitochondria to ARV affects
foetal development. We have demonstrated that oocytes from infertile
HIV-infected HAART-treated women show a decreased mtDNA con-
tent that could explain their poor reproductive outcome [19]. Several
mitochondrial alterations are associated with initiation of mitochon-
drial biogenesis and activation during early states of embryo develop-
ment. The mtDNA content and expression levels of genes involved in
the maintenance and regulation of biogenesis change during human
foetal development. The foetus is exposed to the potentially stressful
in utero environment created by maternal ARV-associated metabolic
toxicities and placental transferred ARVs at critical points in its devel-
opment.
Colleoni et al. have recently described significantly decreased
mtDNA in non-infected women carrying IUGR fetuses compared to
control pregnancies. The authors concluded that in HIV-uninfected
pregnancies mtDNA content and mitochondrial function may help rec-
ognizing adverse perinatal outcome [42]. It is unknown whether
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mitochondrial depletion is a predictor factor for poor pregnancy out-
come in HIV patients. Indeed, only two studies have evaluated the
association between mitochondrial toxicity and poor pregnancy out-
come in HIV-infected pregnant women on HAART. Both analyse mito-
chondrial status in the third trimester of gestation. Nasi et al.
described a decrease in mtDNA content in subcutaneous fat of HIV-
pregnant women taking ARV compared to uninfected women without
ARV [43]. The second report, published by our group, described that
HAART toxicity may cause subclinical mitochondrial damage in blood
of HIV-pregnant women and their newborn compared to uninfected
pregnancies [27]. To our knowledge, the present work is the first lon-
gitudinal study investigating the evolution of mtDNA content, mito-
chondrial protein synthesis, mitochondrial function and apoptotic
caspase activation in HIV-infected women during pregnancy or the
potential use of these parameters as pronostics factors to predict
adverse perinatal outcome in HIV pregnancies.
In this study we found a higher prevalence of adverse perinatal
outcome in the HIV cohort compared with controls, thereby confirm-
ing the deleterious effect of both the virus and the treatment on foetal
development as well as validating our sample.
During pregnancy, we observed a progressive decrease in mtDNA
content which was significantly higher in HIV-infected pregnant
women. Our results agree with two previous studies performed in
pregnant women which evaluated blood mtDNA content along preg-
nancy [38–42]. Colleoni et al. reported a significant decrease in
mtDNA content in the blood of uninfected pregnant women in the
first, second and third trimesters compared to non-pregnant women
[42]. This decrease was higher in HIV-pregnancies [38] and, accord-
ing to the present findings, would be partially developed along preg-
nancy.
The mtDNA depletion observed in our HIV cohort was even
greater in na€ıve pregnant women who started HAART during the sec-
ond trimester of gestation compared with pregnancies under HAART
prior to conception. This finding could be explained by the initiation of
ARV, abruptly increasing mitochondrial toxicity and resulting in a dra-
matic decrease in mtDNA content which is maintained over time. This
theory is in agreement with a previously published study by our group
[44].
In our study we have demonstrated that a decrease in mtDNA
leads to a significant reduction in downstream mitochondrial protein
synthesis and mitochondrial function in pregnancies complicated with
HIV infection and ARV. Correlations were found between genetic and
functional mitochondrial parameters demonstrating (i) that proper
mitochondrial functionalism relies on proper levels of mtDNA copies
and (ii) the etiopathogenic cause of the dysfunction observed is
because of NRTI toxicity and interference in mtDNA replication.
Under pathological conditions, mitochondrion triggers apoptosis.
Consequently, any mitochondrial disarrangement may have fatal cell
consequences. An important pre-requisite for a successful pregnancy
is that the maternal immune system does not reject the foetus and
thus, cellular immune response could be essential. Apoptosis has
also been shown to play an important role in promoting maternal
immune tolerance to paternal antigens expressed by trophoblastic
cells [45], which is a physiological process during pregnancy. While
apoptosis is thought to be important as a normal physiological feature
for foetal or placental development, enhanced levels may also be
involved in the pathological conditions. Higher apoptosis levels may
have implications in adverse perinatal outcome. A greater incidence
of apoptosis has been observed in conditions such as pre-eclampsia
and IUGR, suggesting that appropriate regulation of apoptosis is
important for normal pregnancy [46].
Blood cells apoptotic activation of caspase-3 increased along
pregnancy in both our cohort of HIV-patients under treatment and in
controls. In uninfected pregnancies the apoptotic rate of caspase-3
activation probably increases as a physiological mechanism to delete
newborn cells from the maternal blood [45]. However, this increase
was significantly enhanced in HIV pregnancies in concordance with
accumulated, previous NRTI exposure. Apoptosis of uninfected cells
is a key element of HIV pathogenesis and is believed to be the driving
force behind the selective depletion of CD4+ T cells leading to immun-
odeficiency. We found that HIV infection and ARV have a significant
impact on apoptotic activation of PBMC’s caspases. In the first trime-
ster of gestation HIV-positive women showed higher levels of PBMC
apoptotic caspase-3 activation specially in those with longer exposure
to HIV or NRTI. Additionally, at delivery, HIV-infected women longer
exposed to NRTI showed higher levels of PBMC caspase-3 activation.
These results are in agreement with previously published work [38].
However, we did not find any association between mtDNA con-
tent, mitochondrial protein synthesis, mitochondrial function or apop-
totic caspase activation and adverse perinatal outcome in HIV
patients. We found an increased prevalence of adverse pregnancy
events in HIV pregnancies and enhanced trends towards mitochon-
drial impairment and apoptotic caspase activation along pregnancy in
accordance to HIV or NRTI exposure, but did not find a significant
association between these molecular findings and poor obstetric out-
come. We did not find the presence of different patterns of mitochon-
drial toxicity and apoptotic caspase activation in HIV pregnancies
correlating with a distinct pattern of clinical expression, probably
because of the small sample size, which made patient stratification
and statistical findings difficult. Other constraints of this study may
be the presence of different types of HAART and time-exposure to
HIV or ARVs, characteristic of observational studies and personalized
treatment interventions, which on the other hand may enclose find-
ings to reality. The inclusion of a control group of non-pregnant HIV-
infected and treated women may have been useful to assess longitu-
dinal mitochondrial and apoptotic toxicity of HIV and HAART without
potential gestation interference. However, such studies are exten-
sively documented in the bibliography [47] and, additionally, the
interest of the present work was focused on obstetric problems and,
thus, in pregnant women. Additionally, to overcome methodological
pitfalls and strength, the significance of reported findings, the deregu-
lation of bioenergetics capacity or apoptotic status in studied patients
was assessed, in parallel, by Western Blotting and functional mea-
sures, which rendered similar results. However, detailed mechanistic
pathways underlying HIV- and HAART-associated toxicity in HIV preg-
nancies should be further elucidated.
In conclusion, although pathogenetically plausible with these find-
ings, it is not yet possible to prove a cause–effect association of
adverse perinatal outcome with mitochondrial and apoptotic toxicity
of HIV and NRTIs exposure during pregnancy. As a consequence, we
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did not succeed in the secondary objective of this study; identify epi-
demiological risk factors and prognostic markers of mitochondrial
toxicity or apoptotic caspase activation for potentially associated poor
clinical results in HIV-infected mothers.
Several groups have proposed that monitoring possible markers
of mitochondrial dysfunction in peripheral blood of pregnant women
may be useful for detecting preclinical NRTI toxicity. Furthermore,
prospective studies in HIV pregnancies under HAART are needed, to
determine whether the incidence of mitochondrial disorders differs
according to the regimen used and to develop predictive models to
identify mothers–infants at highest risk. In an era of expanding treat-
ment options, minimizing toxicities is possible and necessary. The
role of mitochondria and apoptosis in physiological conditions must
also be clarified to define the relevance of mitochondrial or apoptotic
alterations in HIV pregnancies.
As a proof-of-concept, the present study has been conducted in a
single-site centre and in a limited population. The short- and long-
term health consequences of mitochondrial toxicity and apoptosis in
HIV pregnancies should be further investigated in larger cohorts.
There is a crucial need to fully understand the scope and depth of this
problem through continued basic and clinical research evaluating the
effects of foetal and maternal ARV exposure to better understand the
morbidity associated with mitochondrial toxicity or apoptosis in preg-
nant women exposed to HIV and HAART. The current challenge is to
design new ARV schedules with reduced harmful mitochondrial and
apoptotic effects.
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